Literature DB >> 535135

Evaluation of early doxorubicin-induced cardiotoxicity by means of systolic time intervals.

F Villani, G Beretta, A Guindani.   

Abstract

Systolic time intervals (PEP/LVET ratio) were used for detection of acute variations in myocardial contractility after a single dose of 30, 60, or 75 mg of doxorubicin/m2. This drug induces an acute impairment of left ventricular function (increase in the PEP/LVET ratio) detectable 1 h after doxorubicin injection. The phenomenon appears to be dose-related, with a threshold dose of 30-40 mg/m2. The decrease in myocardial contractility is fully reversible within 24 h, at least after the first dose. This kind of evaluation appears applicable to phase I studies of new anthracycline derivatives.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 535135     DOI： 10.1007/BF00254740

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  8 in total

1.  [Polycardiographic evaluation of the cardiotoxicity of adriamycin].

Authors:  F Villani; G Beretta; A Guindani; A Pagnoni; S Vivarelli
Journal:  G Ital Chemioter       Date:  1975 Jan-Dec

2.  Systolic time intervals in heart failure in man.

Authors:  A M Weissler; W S Harris; C D Schoenfeld
Journal:  Circulation       Date:  1968-02       Impact factor: 29.690

3.  Systolic time intervals in monitoring adriamycin-induced cardiotoxicity.

Authors:  S P Balcerzak; J Christakis; R P Lewis; H M Olson; L Malspeis
Journal:  Cancer Treat Rep       Date:  1978-06

4.  Influence of adriamycin on calcium exchangeability in cardiac muscle and its modification by ouabain.

Authors:  F Villani; F Piccinini; P Merelli; L Favalli
Journal:  Biochem Pharmacol       Date:  1978-03-15       Impact factor: 5.858

5.  Systolic time intervals in monitoring for anthracycline cardiomyopathy in pediatric patients.

Authors:  R J Hutchinson; C Bailey; D Wood; M H Donaldson
Journal:  Cancer Treat Rep       Date:  1978-06

6.  Serial studies of cardiac function in patients receiving adriamycin.

Authors:  I C Henderson; L J Sloss; N Jaffe; R H Blum; E Frei
Journal:  Cancer Treat Rep       Date:  1978-06

7.  Invasive and noninvasive methods of assessing adriamycin cardiotoxic effects in man: superiority of histopathologic assessment using endomyocardial biopsy.

Authors:  J W Mason; M R Bristow; M E Billingham; J R Daniels
Journal:  Cancer Treat Rep       Date:  1978-06

8.  Echocardiographic assessment of left ventricular function during the injection of adriamycin.

Authors:  G Björkhem; S Garwicz
Journal:  Acta Paediatr Scand       Date:  1977-09
  8 in total
  3 in total

1.  Hemodynamic effects of chronic 4'epi-adriamycin administration.

Authors:  J Milei; J J Ale; G Garay; F Otero; A Z Comba; H O Gugliotta; R A Storino
Journal:  Cardiovasc Drugs Ther       Date:  1990-12       Impact factor: 3.727

2.  The Cardiotoxic Mechanism of Doxorubicin (DOX) and Pegylated Liposomal DOX in Mice Bearing C-26 Colon Carcinoma: a Study Focused on microRNA Role for Toxicity Assessment of New Formulations.

Authors:  Kamal Razavi-Azarkhiavi; Mahmoud Reza Jaafari; Khalil Abnous; Bibi Marjan Razavi; Amir Hossein Jafarian; Faezeh Vahdati Hassani; Kobra Shirani; Gholamreza Karimi
Journal:  Pharm Res       Date:  2017-05-30       Impact factor: 4.200

Review 3.  Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties.

Authors:  J Bouma; J H Beijnen; A Bult; W J Underberg
Journal:  Pharm Weekbl Sci       Date:  1986-04-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.